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Abstract 12 
Communicating essential research information to low literacy research participants in Africa is highly 13 
challenging, since this population is vulnerable to poor comprehension of consent information. 14 
Several supportive materials have been developed to aid participant comprehension in these 15 
settings. Within the framework of a pneumococcal vaccine trial in The Gambia, we evaluated the 16 
recall and decay of consent information during the trial which utilized an audio-visual tool called 17 
‘Speaking Book’, to foster comprehension amongst parents of participating infants. The Speaking 18 
Book was developed in the two most widely spoken local languages. 19 
Four-hundred and nine parents of trial infants gave consent to participate in this nested study and 20 
were included in the baseline assessment of their knowledge about trial participation. An additional 21 
assessment was conducted approximately 90 days later, following completion of the clinical trial 22 
protocol. 23 
All parents received a Speaking Book at the start of the trial. Trial knowledge was already high at the 24 
baseline assessment with no differences related to socio-economic status or education. Knowledge 25 
of key trial information was retained at the completion of the study follow-up. The Speaking Book 26 
(SB) was well received by the study participants. We hypothesize that the SB may have contributed 27 
to the retention of information over the trial follow-up. Further studies evaluating the impact of this 28 
innovative tool are thus warranted. 29 
 30 
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Introduction 46 
Individual agreement, or informed consent, is a process by which a potential participant voluntarily 47 
confirms his or her willingness to participate in a clinical trial after having received necessary 48 
information about all aspects relevant to inform this decision. This is a critical requirement for 49 
participation in biomedical research and should include a demonstration of recall of the purpose of 50 
the trial, potential benefits and harm, and participants’ obligations and responsibilities. 1  The 51 
informed consent process does not end at signing off the consent form, but continues throughout 52 
the trial 2,3 and participants need to understand their rights including withdrawal at any time without 53 
the need to give a reason for doing so.  54 
 55 
When clinical trials are conducted in populations with low literacy levels, the process of informed 56 
consent encounters several challenges related but not limited to the basic principles of autonomy, 57 
voluntariness and comprehension. It is especially difficult for illiterate participants to appreciate how 58 
clinical trials differ from medical care, since investigators perform research procedures with the 59 
same medical instruments that are used in standard care. 4-6 The perceived authority of a physician 60 
in these settings also often makes potential participants reluctant to ask questions or express  61 
unwillingness to participate in the trial. 7 In addition, misunderstanding of trial procedures such as 62 
randomization 8 are common. 63 
There are particular challenges faced during the consent process in sub-Saharan Africa, given the 64 
combination of low level of literacy in the population and high number of spoken rather than written 65 
local languages. In many instances in these settings, the ICD is written in English or the 66 
corresponding official language of the country and, for illiterate participants, it is verbally 67 
interpreted by trained study staff during the consent process using their spoken language. 9 Consent 68 
of illiterate participants is also supported by the presence of a literate impartial witness who should 69 
be present throughout the discussion to attest that the information discussed is consistent with the 70 
ICD and the process follows internationally acceptable ethical standards. The literate witness should 71 
be independent of the trial and should read and translate any written information supplied to the 72 
potential participant. 1 Identifying and recruiting independent, literate witnesses poses an additional 73 
challenge. 74 
 75 
In order to enable research participants to make an informed decision based on understanding of 76 
consent information, a number of innovative techniques have been developed. These include use of 77 
flower diagrams, flip charts with pictures, audio or audio-visual recordings and person-to-person 78 
discussions amongst others. 3,10-13 Speaking Books (SB) have been developed to aid understanding 79 
and recall of trial information in low literacy communities. The SB is A5 size, has hard covers and 80 
large pages with each page of the book graphically illustrated with simple text relevant to the 81 
illustration.  Every SB also has a plastic panel with a built in battery, which hosts a series of push 82 
buttons, each of which corresponds to a specific page in the speaking book. When activated, the 83 
‘push buttons’ trigger a soundtrack of the text on the relevant page. The soundtrack is narrated by a 84 
native speaker with the appropriate voice and tonal quality, and is thus vocalised to the person using 85 
the book. 14 SB have been piloted among English speakers 14,15 but no study has examined their role 86 
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when provided in participants’ local languages despite the fact that the book has been translated 87 
into several local languages in Africa and Asia. 88 
 89 
The nested study presented here assessed the recall of parents of infants participating in a 90 
pneumococcal vaccine trial in a peri-urban setting in The Gambia, West Africa. This study was nested 91 
within a phase III randomised, open-label trial aimed at evaluating the safety, tolerability and 92 
immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) formulated in multi-dose 93 
vials given with routine paediatric vaccinations in healthy infants (Idoko et al , under review, 94 
Vaccine). The adult female literacy rate in this setting is about 30% 16 and health-seeking behaviour is 95 
governed by traditions rather than modern health care norm. 17 We also assessed factors associated 96 
with decay of knowledge of key  information relating to the parent trial 18 during the three  month 97 
follow-up period employing a descriptive study design. The consent process for the parent trial 98 
utilized the SB with information delivered in the main local languages in Western Gambia – Wollof 99 
and Mandinka. 100 
Results 101 
Between January and May 2014, 500 infants were recruited for the parent trial. 428 parents (85.6%) 102 
were approached for this nested study and 409 (95.6%) parents (all mothers in this case) gave oral 103 
consent to answer the questions of the AQ in addition to the ACQ. The analysis was performed on 104 
information available at the two time points assessed from 377 respondents (92.1%).  105 
 106 
Most respondents were unemployed women (70.6%); 17.2% had no formal education, over 40% had 107 
five or fewer years of formal education and approximately three quarters were in a monogamous 108 
family (Table 1), 109 
 110 
 111 
For the 10 ACQ questions, over 99% of women during pre-trial assessment answered all of the 112 
questions correctly at the first attempt and the remaining 1% at the second attempt. At the end of 113 
the trial, all women responded correctly to the 10 questions in the only attempt given (Table 2). 114 
 For the AQ, which was specific for the nested study, the frequency of correct answers was lower 115 
with 6 out of 10 questions having less than 90% of correct answers pre-trial; and only 2 out of 10 116 
post-trial.  Questions with double negative statements like ‘Your child will not receive other vaccines 117 
for his/her age while in the study’ were answered correctly by 71.1% of women pre-trial and 76.9% 118 
post-trial compared to over 98% correct responses at both time points, for more straightforward 119 
questions like ‘You can request a form to take home and discuss with your family’ (Table 2). Overall, 120 
the proportion of correct answers post-trial was higher than pre-trial, with significant differences for 121 
“A malaria test will never be done if your child develops fever” (pre: 80.9% correct versus post: 122 
94.7%, p<0.001); “the doctor will stop the study for your child if s/he thinks that your baby could be 123 
hurt” (pre: 86.7% correct versus post: 97.3%, p<0.001) and “If your baby is unwell 5 days after 124 
vaccination he/she must be admitted to hospital” (pre: 87.5% correct versus post: 99.6%, p<0.001). 125 
No differences in level of trial knowledge were found by age, occupation, years of education, religion 126 
or family type either at pre or post-trial (Table3). A difference between time points was only 127 
observed as an increase in knowledge among farmers (from 75% to 90%), which was the group with 128 
lowest knowledge pre-trial. This difference was however not statistically significant as the 129 
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confidence intervals at both time points overlapped and the 95% confidence interval for the mean 130 
difference just crosses 0 (-30.2 - 0.2) . 131 
 132 
 133 
Participant responses to open ended questions 134 
Most women (95.5%) did not recommend any change.  Among those suggesting improvements 135 
(multiple answers permitted), the most common suggestions were addition of other local languages 136 
such as Fula, or Jola (2.7%);  followed by increasing the speaker volume (0.8%), the need for extra 137 
batteries (0.5%) and reduction in the size of the book (0.5%).  97.9% shared the book with other 138 
family and friends. 139 
The key messages stated by respondents to the open ended questions relating to their recall from 140 
the SB are summarized as follows;  141 
1) It provided a better recall of research ethics e.g. [“your child’s confidential information will be 142 
protected”, “it is your decision to participate in the trial”].  143 
2) It provided a better recall of clinical research e.g. [“the field worker will visit for five days after 144 
vaccination, “checking the blood is the most important part to me because without this it’s 145 
impossible to know what effect the vaccine has had”].  146 
3)  It provided information on improving child health e.g. *“attending monthly maternal child health 147 
clinics for vaccination can improve the health of your child”],  148 
4) It explained the importance of vaccination e.g. *“I now understand why we take our children for 149 
the monthly clinics and the importance of participating in research studies”, “monthly vaccination is 150 
important, can protect your child from diseases] 151 
5) It stimulated interest in the trial e.g. [One 25year old respondent said “I listened to the book in my 152 
neighbours’ home and decided to come and find out more about the trial”]. 153 
 154 
Discussion  155 
In this study, we demonstrated that trial participants receiving a speaking book had a good 156 
knowledge of the trial procedures at the start of the trial and retained this information during the 90 157 
days of trial procedures.  158 
Although trial information was generally well understood, the answers to more difficult questions, 159 
such as those with double negative statements or related to clinical care, were less accurate (70-80% 160 
correct answers compared to over 90%).  This is probably a consequence of the generally low 161 
educational levels in our study population. In both developed and developing country contexts it has 162 
been shown that educational level was an independent predictor of comprehension. 19,20 In contrast, 163 
however, educational level was not associated with comprehension in our study as previously shown 164 
in The Gambia, within a largely illiterate population. 21,22 It may be that differences in education 165 
within the study population are too lean to detect differences and is a subject for future research. 166 
Interestingly, we noted that there was a trend of improvement of trial knowledge over the course of 167 
the follow-up period for all age groups, occupations, educational levels, religions and family types. 168 
We speculate that this trend (though not statistically significant) may, in part, have been due to the 169 
use of the SB which encouraged continuous exposure to key trial information. 23 Our statement is 170 
supported by the reports of high SB use and the sharing of the SB with other family members and 171 
friends which implies continuous exposure to the trial information. Studies with comparator groups 172 
where some participants do not receive the SB would however be necessary to confirm this 173 
hypothesis as mere participation in the trial and other trial procedures could also account for this 174 
trend. Previous studies which have assessed the use of multimedia tools 10,21 to assess recall of key 175 
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trial information one week after initial consent have also shown improvements in trial participants 176 
knowledge of clinical trials, and their rights and responsibilities. Our study differs as the follow-up 177 
period was longer (90 days) compared to the shorter follow-up of 1 week in other studies.  178 
 179 
Most of the women appeared satisfied with the SB and did not suggest any improvements (95.5%). 180 
Among suggested improvements were changes to portability of the book and increased battery life. 181 
The suggestion to include other major oral languages in the SB, although ideal, it would be 182 
impractical for logistical reasons due to the number of minor languages in the country. Still, in 183 
countries with several local languages the limitation of the number of languages to be added to the 184 
SB would always be a limitation to consider. We also observed that the SB is an additional tool for 185 
expanding the information of an ongoing trial in the community, based on the responses of one of 186 
our trial participants indicating that she first heard about our trial at a neighbors’ home by listening 187 
to her SB. 188 
 189 
Beyond the limitations of the SB, this ancillary study has some limitations based on the study design, 190 
given that all study participants had access to the SB prior to the assessment and thus there was no 191 
comparator group to assess the real advantages of the book. We only included participants who had 192 
passed the baseline assessment to the parent trial. We note however that only 2 out of 526 193 
participants were excluded from the main trial for failing the baseline comprehension test. In 194 
addition, the follow-up period was short and studies with longer follow up may reveal some decay in 195 
consent information.  The population in the Gambia also has long term exposure to clinical research 196 
with the presence of the Medical Research council Unit for over 70 years. This may also have 197 
impacted understanding and subsequent recall of information. 198 
 199 
Conclusion 200 
 201 
 202 
The awareness of trial information was generally high in this illiterate population.  203 
There was no apparent decay in consent information or change in recall in any of the 204 
sociodemographic subgroups.  205 
The SB has potential to educate low literacy communities regarding participation in clinical trials in 206 
settings where written language translation is a challenge and may have benefits beyond education 207 
for the specific trial. 208 
Methods 209 
 210 
Study design and population  211 
 212 
The parent  trial enrolled healthy infants aged 42 to 70 days weighing 3·5 kg or more who presented 213 
for vaccination at Fajikunda Major Health Centre (FKHC), a government run health facility in western 214 
Gambia that vaccinates approximately 5,000 children per year. Details of entry and exclusion criteria 215 
are available at (ClinicalTrials.gov, NCT01964716). Children were recruited before the first dose of 216 
PCV13 and were visited daily for 5 days after each vaccination to assess for local and systemic 217 
adverse vaccine reactions, and seen monthly at the health facility until one month after the third 218 
dose of PCV13. Parents who gave consent for their infants to participate in the trial were 219 
approached to participate in this descriptive nested study.  220 
 221 
 222 
Consent process  223 
 224 
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Community leaders including household heads, women and youth leaders and local religious leaders 225 
were visited to give information regarding the trial. This was followed by large community 226 
sensitisation meetings at which the trial team explained key trial information and addressed 227 
concerns raised on the cultural and social appropriateness of some of the trial procedures such as 228 
frequency of appointments and what each clinic/home visit would entail.  229 
 230 
The trial staff subsequently approached potential participants at the Infant Welfare clinic located 231 
within FKHC, and held discussions about the parent trial with parents who brought their infants for 232 
routine immunisations/care.  The parents were encouraged to seek clarity on any aspect of the 233 
parent trial. The trial staff then asked the parent a set of questions to ensure understanding, and 234 
provided a copy of the ICD to be taken home to discuss with other family members. These steps are 235 
in accordance with the routine consent process for trials of this nature in this setting. 236 
 237 
Following this, meetings to discuss the contents of the ICD and answer any questions from other 238 
family members identified by the parent were arranged. Individuals who continued to express 239 
willingness to participate in the study received a copy of the SB as required by the parent trial. The 240 
SB was developed in two major Gambian languages:   - Mandinka and Wolof. The book explained in 241 
clear local dialect the basic elements of the trial participation including trial purpose, participant 242 
rights, and their roles and responsibilities (Figure 1). The research staff further explained to parents 243 
who gave consent how to use the book, including how to switch between the two local language 244 
recordings.  245 
Parents were then requested to visit the FKHC for informed consent procedure (including another 246 
explanation of the consent document and an opportunity to ask questions).  Assessment of eligibility 247 
was also performed by the trial clinicians during this visit. Consent information was given only in 248 
Mandinka, Wolof or English, based on participant preference.  249 
 250 
Following these procedures, participant recall of key trial information was assessed using an 251 
interviewer-administered Assessment of Consent recall Questionnaire (ACQ).   252 
 253 
The ACQ was a 10-item questionnaire with a ‘true’ or ‘false’ response. Domains covered by this 254 
questionnaire included purpose of the trial, confidentiality, voluntariness and trial procedures. A 255 
score of 1 was assigned for each question answered correctly and 0 for questions answered 256 
incorrectly.  If the total score was 10 the participant was enrolled. If the score was 9, the question 257 
wrongly answered was reviewed with the parent and the participant enrolled. A score of 8 or below 258 
required a review of trial information followed by a second attempt at the ACQ. If any error was 259 
made at the second attempt, the participant was not eligible for enrolment into the parent trial.  260 
 261 
Parents of infants recruited in the parent trial were subsequently approached to participate in this 262 
nested study by giving oral consent. Where consent was given, an Additional Questionnaire (AQ) 263 
comprising of 10 question items (8 true or false and two open ended) was then administered on the 264 
day of enrolment) asking more in-depth questions regarding the trial. Only one attempt was allowed 265 
to respond at these questions and the results did not compromise the participation in the parent 266 
trial. Additional questions on experience of use of the SB were asked post trial (90 days post 267 
enrolment) along with the re- administration of the ACQ and AQ.  268 
 269 
The knowledge of informed consent information was determined by the responses to questions in 270 
the two questionnaires. 271 
 272 
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This study utilized a speaking book narrated in the well known voice of a popular local media 273 
personality. 274 
 275 
 276 
Statistical methods 277 
 278 
Statistical analysis 279 
 280 
Data analysis 281 
Twenty items from both questionnaires were used to assess the knowledge of participants, 282 
estimated by the proportion of correct responses given by the participants. Socio-demographic 283 
factors (age, education level, religion, family type and occupation) and each knowledge assessment 284 
item, all categorical, were summarized by proportion. Fisher’s exact tests for association were 285 
applied to compare the proportions of correct answers for each item between visits. 286 
Further, ordinary least square (OLS) linear regression analysis was applied to estimate and compare 287 
mean proportions of correct answers (with their 95% confidence intervals) between and within 288 
different levels of socio-demographic factors. Separate analyses were conducted at the two time 289 
points and for the paired differences between the two visits (knowledge decay). Overall p values of 290 
associations were estimated for the outcomes (visit one and visit four), as well as specific p values 291 
for within socio-demographic group knowledge decay. 292 
All analyses were conducted in Stata version 12 (StataCorp, USA). A two-sided p value <0.05 was 293 
considered to be statistically significant.  294 
Open ended questions were analyzed through content analysis of participant responses 18. 295 
 296 
Ethical consideration 297 
The Gambia Government/MRC Joint Ethics Committee approved the parent trial and this nested 298 
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 377 
 Table1: Socio-demographic characteristics of mothers of infants enrolled to answer additional 378 
questions on consent during parent trial 379 
Variable  n (%) 
Age groups of Respondent 
(years)   
   18-24 147 (39.0%) 
   25-29 104 (27.6%) 
   30+ 126 (33.4%) 
Occupation   
   Civil Servant  14 (3.7%) 
   Farming    1 (0.3%) 
   Others  29 (7.7%) 
   Trading  67 (17.8%) 
   Unemployed 266 (70.6%) 
Years Of Education    
     0   65 (17.2%) 
   1-5   90 (23.9%) 
   6-10 140 (37.1%) 
   11-14   75 (19.9%) 
   15+    7 (1.9%) 
Family Type   
   Monogamy 273 (72.4%) 
   Polygamy 100 (26.5%) 
   Single Parent     4 (1.1%) 
Total 377 
 380 
  381 
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Table2:  Assessment of consent recall and decay in knowledge between visit 1 (D0) and visit 4 (D 382 
90) 383 
Question 
Day 0 
(pre-trial) 
Day 90 
(post trial) 
p-
value 
Questions requiring correct answers prior to 
trial enrolment (ACQ) 
   N 377 377  
This study will assess the pneumococcal vaccine 
already used in Gambia. (attempts)      1.00 
   1 376 (99.7%) 377 (100.0%)   
   2      1 (0.3%)      0 (0.0%)   
Your child will receive trial vaccines on 2 
occasions during the study. (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)     0 (0.0%)   
This study requires that you come to the clinic 
for a total of 4 visits. (attempts)     0.25 
   1 374 (99.2%) 377 (100.0%)   
   2      3 (0.8%)      0 (0.0%)   
This new vaccine will protect your child against 
polio. (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)     0 (0.0%)   
A participant in this trial may receive the trial 
vaccine (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2     2 (0.5%)     0 (0.0%)   
1 teaspoon of blood will be collected from your 
child at the 4th visit. (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)     0 (0.0%)   
You are free to withdraw from this study at any 
time. (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)      0 (0.0%)   
Study nurses can tell anyone about your 
participation in the study (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)      0 (0.0%)   
You will be visited by a field worker for 5 days 
after each vaccination (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)      0 (0.0%)   
Your child’s participation in the study will be for 
a period of 4 months (attempts)     0.50 
   1 375 (99.5%) 377 (100.0%)   
   2      2 (0.5%)      0 (0.0%)   
 
Additional questions to assess consent recall 
and decay (AQ) 
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Vaccines will help to protect your child against 
getting diseases caused by germs.  
     0.75 
   False     4 (1.1%)     6 (1.6%)   
   True 373 (98.9%) 371 (98.4%)   
How Many Babies need to be Recruited, n (%)     0.53 
   (10-400)   37 (9.8%)   43 (11.4%)   
   500 333 (88.3%) 330 (87.5%)   
   (600-2000)     7 (1.9%)      4 (1.1%)   
When your child receives vaccines his/her body 
produces super heroes to fight infection     0.049 
   False     6 (1.6%)   16 (4.2%)   
   True 371 (98.4%) 361 (95.8%)   
Your child will not receive other vaccines for 
his/her age while in the study      0.081 
   False 268 (71.1%) 290 (76.9%)   
   True 109 (28.9%) 87 (23.1%)   
You can request a form to take home and discuss 
with your family     0.75 
   False     6 (1.6%)     4 (1.1%)   
   True 371 (98.4%) 373 (98.9%)   
A malaria test will never be done if your child 
develops fever     <0.001 
   False 305 (80.9%) 357 (94.7%)   
   True   72 (19.1%)   20 (5.3%)   
Which other person can sign the consent form?     0.77 
   Husband 348 (92.3%) 353 (93.6%)   
   Mother     9 (2.4%)      8 (2.1%)   
   Other   20 (5.3%)    16 (4.2%)   
Babies may have pain but not swelling when a 
vaccine is given     0.24 
   False    70 (18.6%)    57 (15.1%)   
   True 307 (81.4%) 320 (84.9%)   
The doctor will stop the study for your child if 
he/she thinks that your baby could be hurt     <0.001 
   False   50 (13.3%)   10 (2.7%)   
   True 327 (86.7%) 367 (97.3%)   
If your baby is unwell  5 days after vaccination he 
must be admitted to hospital.     <0.001 
   True   47 (12.5%)     9 (2.4%)   
   False 330 (87.5%) 368 (97.6%)   
 384 
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Table 3: Assessment of consent recall and decay in knowledge based on socioeconomic 386 
parameters. 387 
Variables 
Day 0 
(pre trial) 
Day 90 
(post trial) 
Difference     
(Visit1-Visit4) 
 
Mean(95%CI) 
P 
value Mean(95%CI) 
P 
value Mean(95%CI) 
     
 
Age of Respondent 
(years) 
 
0.570 
 
0.768  
18-24 87.8(86.7 ; 88.9) 
 
89.3(88.6 ; 90.0) 
 
 -1.5(-2.7 ; -0.2) 
25-29 88.7(87.4 ; 90.0) 
 
89.0(88.2 ; 89.8) 
 
 -0.3(-1.8 ; 1.2) 
30+ 89.8(88.6 ; 91.1) 
 
89.0(88.3 ; 89.7) 
 
  0.8(-0.5 ; 2.2) 
Occupation 
 
0.144 
 
0.821  
Civil Servant 89.6(86 ; 93.3) 
 
88.9(86.7 ; 91.1) 
 
   0.7(-3.4 ; 4.8) 
Farming 75.0(61.4 ; 88.6) 
 
90.0 (81.8 ; 98.2) 
 
-15.0(-30.2 ; 0.2) 
Other 86.7(84.2 ; 89.2) 
 
88.6(87.1 ; 90.1) 
 
-  1.9(-4.7 ; 0.9) 
Trading 89.1(87.4 ; 90.8) 
 
89.6(88.6 ; 90.6) 
 
-  0.5 (-2.4 ; 1.3) 
Unemployed 88.9(88.0 ; 89.7) 
 
89.1(88.6 ; 89.6) 
 
-  0.2 (-1.1 ; 0.7) 
Education Level 
 
0.786 
 
0.14  
Arabic Only 89.3(88 ; 90.7) 
 
88.5(87.7 ; 89.3) 
 
 0.8(-0.7 ; 2.3) 
None 88.5(86.8 ; 90.2) 
 
89.1(88.1 ; 90.1) 
 
-0.6(-2.5 ; 1.3) 
Part Primary 87.9(85.3 ; 90.4) 
 
88.8(87.2 ; 90.3) 
 
-0.9(-3.8 ; 2) 
Part Secondary 88.8(87.4 ; 90.1) 
 
89.8(89.0 ; 90.5) 
 
-1.0(-2.5 ; 0.4) 
Part Tertiary 86.9(82.0 ; 91.7) 
 
86.9(84.0 ; 89.7) 
 
 0.0(-5.4 ; 5.4) 
Primary 85.9(81.8 ; 90) 
 
90.9(88.5 ; 93.4) 
 
-5.0(-9.6 ; -0.4) 
Secondary 89.4(87.2 ; 91.6) 
 
88.7(87.4 ; 90) 
 
 0.6(-1.8 ; 3.1) 
Tertiary 89.0(85.5 ; 92.5) 
 
90.3(88.2 ; 92.4) 
 
-1.3(-5.3 ; 2.6) 
Years Of Education 
(caretaker) 
 
0.86 
 
0.496  
0 88.5(86.8 ; 90.2) 
 
89.1(88.1 ; 90.1) 
 
-0.6(-2.5 ; 1.3) 
1-5 89.2(87.7 ; 90.6) 
 
88.7(87.9 ; 89.6) 
 
 0.4(-1.2 ; 2.1) 
6-10 88.3(87.2 ; 89.5) 
 
89.5(88.8 ; 90.2) 
 
-1.1(-2.4 ; 0.1) 
11-14 89.2(87.6 ; 90.8) 
 
89.2(88.3 ; 90.1) 
 
 0.0(-1.8 ; 1.8) 
15+ 89.3(84.1 ; 94.5) 
 
87.1(84.1 ; 90.2) 
 
 2.1(-3.6 ; 7.9) 
Religion 
 
0.252 
 
0.524  
Christianity 86.1(81.6 ; 90.7) 
 
90.0(87.3 ; 92.7) 
 
-3.9(-9.0 ; 1.2) 
Islam 88.8(88.1 ; 89.5) 
 
89.1(88.7 ; 89.5) 
 
-0.3(-1.1 ; 0.5) 
Family Type 
 
0.808 
 
0.257  
Monogamy 88.6(87.8 ; 89.4) 
 
89.1(88.6 ; 89.6) 
 
-0.5(-1.4 ; 0.4) 
Polygamy 89.1(87.7 ; 90.4) 
 
89.0(88.2 ; 89.8) 
 
  0.1(-1.5 ; 1.6) 
Single Parent 90.0(83.2 ; 96.8) 
 
92.5(88.4 ; 96.6) 
 
-2.5(-10.1 ; 5.1) 
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